Aptose Biosciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Aptose Biosciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Aptose Biosciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Aptose Biosciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. It develops innovative medicines to address unmet clinical needs in oncology, with a focus on hematology. The company’s product pipeline includes two oral kinase inhibitors: tuspetinib (HM43239) and luxeptinib (CG-806). Tuspetinib is being evaluated for frontline therapy in newly diagnosed acute myeloid leukemia (AML) and has demonstrated complete responses in relapsed or refractory AML patients. It is also being explored in combination with venetoclax. Luxeptinib targets kinases in myeloid and lymphoid malignancies and has shown tumor shrinkage in trials for relapsed B-cell leukemias. Aptose operates primarily in the biotechnology and pharmaceutical industries, serving healthcare providers and patients in need of advanced cancer treatments. Aptose is headquartered in Toronto, Ontario, Canada.
Headquarters
Canada
Address
Suite 5300, TD Bank Tower Box 48, 66 Wellington Street West, Toronto, Ontario, M5K1E6
Website
www.aptose.com
Telephone
1 858 9262730
No of Employees
14
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
APTOF (OTC)
EPS
XYZ
Net Income (2024)
XYZ
-0.1%
(2024 vs 2023)
Market Cap*
$4.3M
* As of and is in US$
Aptose Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Tuspetinib: Myeloid Tumors |
| Luxeptinib: B-cell and Myeloid Tumors |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Ownership Changes | In June, the company was acquired by Hanmi Pharmaceutical Co Ltd, a biotechnology company. |
| 2024 | Contracts/Agreements | In August, the company secured a US$10 million loan from Hanmi Pharmaceutical Co Ltd and began negotiations for a new co-development agreement to accelerate tuspetinib's clinical development. |
| 2023 | Contracts/Agreements | In May, the company entered a US$25 common share purchase agreement and registration rights agreement with an institutional investor. |
Competitor Comparison
| Key Parameters | Aptose Biosciences Inc | AbbVie Inc | Jazz Pharmaceuticals Plc | Rigel Pharmaceuticals Inc | Syndax Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | Ireland | United States of America | United States of America |
| City | Toronto | North Chicago | Dublin | South San Francisco | New York City |
| State/Province | Ontario | Illinois | Dublin | California | New York |
| No. of Employees | 14 | 57,000 | 2,890 | 172 | 298 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William G. Rice, Ph.D. | President; Chief Executive Officer; Chairman | Executive Board | 2013 | 67 |
| Fletcher Payne | Chief Business Officer; Chief Financial Officer; Senior Vice President | Senior Management | 2022 | 63 |
| Rafael Bejar, M.D., Ph.D. | Senior Vice President; Chief Medical Officer | Senior Management | 2020 | 55 |
| Robert B. Killion Jr., Ph.D. | Vice President - CMC | Senior Management | - | - |
| Marc Wiles, Ph.D. | Senior Vice President - Regulatory Affairs | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer